You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

Article metrics

Article menu

Download PDFPDF

XML
Case Report
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

 

Online download statistics by month:

Online download statistics by month: January 2020 to May 2026

AbstractFullPdf
Jan 2020880
Feb 202034340
Mar 202041411
Apr 2020242412
May 2020353515
Jun 202018184
Jul 2020303020
Aug 2020313216
Sep 2020109110104
Oct 2020545433
Nov 2020464643
Dec 2020383851
Jan 2021353532
Feb 2021282815
Mar 2021444430
Apr 2021404129
May 2021363630
Jun 2021303012
Jul 2021444428
Aug 2021404043
Sep 2021313012
Oct 2021525237
Nov 2021292926
Dec 2021383830
Jan 2022363710
Feb 2022192022
Mar 2022252516
Apr 2022414212
May 2022313217
Jun 2022272716
Jul 2022393921
Aug 2022485115
Sep 2022343415
Oct 2022363617
Nov 2022242621
Dec 202227277
Jan 2023333313
Feb 2023292914
Mar 2023434415
Apr 2023212110
May 2023303016
Jun 2023252512
Jul 2023292916
Aug 2023394110
Sep 202326267
Oct 2023343414
Nov 202364649
Dec 2023787811
Jan 2024272716
Feb 2024292910
Mar 2024464617
Apr 2024414110
May 202434379
Jun 2024454422
Jul 2024717312
Aug 2024363814
Sep 2024181813
Oct 2024343516
Nov 2024404116
Dec 2024666622
Jan 2025505016
Feb 2025383816
Mar 2025464610
Apr 2025656613
May 2025181818
Jun 2025202010
Jul 2025110
May 2026550
Total248325061219